资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#PD-L1#
309篇内容 | 5705人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=be71139214f, topicName=PD-L1, introduction=PD-L1, content=null, image=null, comments=309, allHits=5705, url=https://h5.medsci.cn/topic?id=13921, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=18117, tagList=[TagDto(tagId=18117, tagName=PD-L1)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1254895, encodeId=79c812548957e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cell Res:高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制, objectType=article, longId=76606, objectId=6a9fe6606af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a9fe6606af, replyNumber=0, likeNumber=55, createdTime=2016-09-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a9fe6606af, moduleTitle=Cell Res:高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a9fe6606af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254894, encodeId=c3a31254894d9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=雾里看花:PD-1/PD-L1抗体疗效评价的困惑, objectType=article, longId=74309, objectId=5773e430947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5773e430947, replyNumber=0, likeNumber=62, createdTime=2016-08-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5773e430947, moduleTitle=雾里看花:PD-1/PD-L1抗体疗效评价的困惑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5773e430947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254893, encodeId=f0ee125489355, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Science:忘记PD-L1吧,破坏Cdk5也能促进抗肿瘤免疫反应, objectType=article, longId=73598, objectId=b0cde3598a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0cde3598a5, replyNumber=0, likeNumber=73, createdTime=2016-07-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0cde3598a5, moduleTitle=Science:忘记PD-L1吧,破坏Cdk5也能促进抗肿瘤免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0cde3598a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254892, encodeId=b80112548922b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, objectType=article, longId=70377, objectId=eb3fe037703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb3fe037703, replyNumber=0, likeNumber=116, createdTime=2016-06-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb3fe037703, moduleTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb3fe037703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254891, encodeId=97c912548919c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO 2016:罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积, objectType=article, longId=70140, objectId=74afe0140e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74afe0140e6, replyNumber=0, likeNumber=68, createdTime=2016-06-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74afe0140e6, moduleTitle=ASCO 2016:罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74afe0140e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254890, encodeId=771812548901f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature:揭示出增加癌细胞抵抗免疫攻击的PD-L1基因变异, objectType=article, longId=69668, objectId=601c69668a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601c69668a2, replyNumber=0, likeNumber=58, createdTime=2016-06-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601c69668a2, moduleTitle=Nature:揭示出增加癌细胞抵抗免疫攻击的PD-L1基因变异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=601c69668a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254889, encodeId=a4f012548899c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, objectType=article, longId=68717, objectId=7e3c68e17a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e3c68e17a3, replyNumber=0, likeNumber=50, createdTime=2016-05-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e3c68e17a3, moduleTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e3c68e17a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254888, encodeId=7ccc12548887c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗获优先审评权,有望今年9月获批上市, objectType=article, longId=65151, objectId=432f65151fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=432f65151fc, replyNumber=0, likeNumber=55, createdTime=2016-03-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=432f65151fc, moduleTitle=罗氏的PD-L1单抗获优先审评权,有望今年9月获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=432f65151fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254887, encodeId=7269125488e48, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet:PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, objectType=article, longId=64211, objectId=be266421184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be266421184, replyNumber=0, likeNumber=52, createdTime=2016-03-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be266421184, moduleTitle=Lancet:PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be266421184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254886, encodeId=1b4a12548860d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat,联合治疗卵巢癌研究启动, objectType=article, longId=61803, objectId=98bd618032f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98bd618032f, replyNumber=0, likeNumber=34, createdTime=2016-01-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98bd618032f, moduleTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat,联合治疗卵巢癌研究启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98bd618032f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254885, encodeId=d2e9125488579, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=SABC 2015:PD-L1抗体atezolizumab联合白蛋白紫杉醇治疗晚期三阴乳腺癌Ib期临床研究显示良好疗效与安全性(GP28328研究), objectType=article, longId=60902, objectId=5d95609029e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d95609029e, replyNumber=0, likeNumber=62, createdTime=2015-12-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d95609029e, moduleTitle=SABC 2015:PD-L1抗体atezolizumab联合白蛋白紫杉醇治疗晚期三阴乳腺癌Ib期临床研究显示良好疗效与安全性(GP28328研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d95609029e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254884, encodeId=b05212548847c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=SABCS 2015:PD-L1免疫治疗在三阴乳腺癌(TNBC)治疗中显示潜力(JAVELIN研究), objectType=article, longId=60901, objectId=a6706090118, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6706090118, replyNumber=0, likeNumber=65, createdTime=2015-12-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6706090118, moduleTitle=SABCS 2015:PD-L1免疫治疗在三阴乳腺癌(TNBC)治疗中显示潜力(JAVELIN研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6706090118)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254883, encodeId=b6601254883ea, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet:Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, objectType=article, longId=60882, objectId=3e5560882c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5560882c0, replyNumber=0, likeNumber=32, createdTime=2015-12-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5560882c0, moduleTitle=Lancet:Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5560882c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254882, encodeId=57491254882af, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=重磅! 美国前总统卡特脑部癌细胞消失,让世界再次聚焦PD-1/PD-L1重磅炸弹!, objectType=article, longId=60379, objectId=7a10603e94a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a10603e94a, replyNumber=0, likeNumber=56, createdTime=2015-12-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a10603e94a, moduleTitle=重磅! 美国前总统卡特脑部癌细胞消失,让世界再次聚焦PD-1/PD-L1重磅炸弹!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a10603e94a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254881, encodeId=065d125488126, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO 2015:膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展, objectType=article, longId=51776, objectId=99ee51e7685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99ee51e7685, replyNumber=0, likeNumber=65, createdTime=2015-06-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99ee51e7685, moduleTitle=ASCO 2015:膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99ee51e7685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254880, encodeId=d0271254880af, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=MedImmune携手Juno!CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章?!, objectType=article, longId=49896, objectId=41ff498968d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ff498968d, replyNumber=0, likeNumber=64, createdTime=2015-04-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ff498968d, moduleTitle=MedImmune携手Juno!CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章?!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ff498968d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254879, encodeId=aa2312548e986, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究), objectType=article, longId=45645, objectId=3d624564589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d624564589, replyNumber=0, likeNumber=78, createdTime=2015-01-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d624564589, moduleTitle=PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d624564589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254878, encodeId=ffe112548e84d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1领域竞争加剧:百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab, objectType=article, longId=44001, objectId=f44c44001b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f44c44001b8, replyNumber=0, likeNumber=69, createdTime=2014-12-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f44c44001b8, moduleTitle=PD-1/PD-L1领域竞争加剧:百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f44c44001b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254877, encodeId=5c5212548e7a1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ESMO 2014:抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好, objectType=article, longId=40875, objectId=3d03408e567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d03408e567, replyNumber=0, likeNumber=64, createdTime=2014-10-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d03408e567, moduleTitle=ESMO 2014:抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d03408e567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254876, encodeId=0c9012548e67b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=默克雪兰诺启动抗PD-L1免疫疗法II期临床研究, objectType=article, longId=38553, objectId=67103855384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67103855384, replyNumber=0, likeNumber=67, createdTime=2014-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67103855384, moduleTitle=默克雪兰诺启动抗PD-L1免疫疗法II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67103855384)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
PD-L1
2020-05-29
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
Cell Res:高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制
55
0
2016-09-05
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
雾里看花:PD-1/PD-L1抗体疗效评价的困惑
62
0
2016-08-04
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
Science:忘记PD-L1吧,破坏Cdk5也能促进抗肿瘤免疫反应
73
0
2016-07-25
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究
116
0
2016-06-11
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
ASCO 2016:罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积
68
0
2016-06-08
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
Nature:揭示出增加癌细胞抵抗免疫攻击的PD-L1基因变异
58
0
2016-06-03
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌
50
0
2016-05-21
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
罗氏的PD-L1单抗获优先审评权,有望今年9月获批上市
55
0
2016-03-23
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
Lancet:PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好
52
0
2016-03-08
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
PD-L1免疫治疗药物avelumab牵手表观药物entinostat,联合治疗卵巢癌研究启动
34
0
2016-01-09
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
SABC 2015:PD-L1抗体atezolizumab联合白蛋白紫杉醇治疗晚期三阴乳腺癌Ib期临床研究显示良好疗效与安全性(GP28328研究)
62
0
2015-12-22
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
SABCS 2015:PD-L1免疫治疗在三阴乳腺癌(TNBC)治疗中显示潜力(JAVELIN研究)
65
0
2015-12-22
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
Lancet:Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期
32
0
2015-12-22
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
重磅! 美国前总统卡特脑部癌细胞消失,让世界再次聚焦PD-1/PD-L1重磅炸弹!
56
0
2015-12-09
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
ASCO 2015:膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展
65
0
2015-06-09
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
MedImmune携手Juno!CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章?!
64
0
2015-04-29
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究)
78
0
2015-01-18
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
PD-1/PD-L1领域竞争加剧:百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab
69
0
2014-12-14
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
ESMO 2014:抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好
64
0
2014-10-04
回复
smartjoy
(审核中...)
关注
已关注
前往app查看评论内容
#PD-L1#
默克雪兰诺启动抗PD-L1免疫疗法II期临床研究
67
0
2014-08-03
回复
共324条
首页
上一页
下一页
尾页
页码:
16
/17页
20条/页
扫描二维码下载梅斯医学APP
科室
订阅+
更多科室
工具
服务